| 1 |
NCT00698321 |
Completed |
A School-Based HIV/STD Prevention Program to Reduce Risky Sexual Behaviors Among Adolescents in Liberia |
|
- Behavioral: HIV/STD prevention curriculum
- Behavioral: General health promotion curriculum
|
Interventional |
Not Applicable |
- Pacific Institute for Research and Evaluation
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Frequency of unprotected sex
|
866 |
All |
13 Years to 15 Years (Child) |
NCT00698321 |
R21MH082666
DAHBR 9A-ASPA |
|
November 2008 |
March 2011 |
March 2011 |
June 17, 2008 |
May 20, 2013 |
|
- University of Liberia
Monrovia, Montserrado County, Liberia
|
| 2 |
NCT00713752 |
Completed |
Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais |
|
|
Observational |
|
- South East Asia Research Collaboration with Hawaii
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To establish normal values for neuropsychological testing in HIV negative Thais stratified by age (1 decade) and education
- To estimate the learning effect on these test at 6 months and 12 months.
|
494 |
All |
20 Years to 69 Years (Adult, Senior) |
NCT00713752 |
SEARCH002 |
|
February 2008 |
December 2013 |
December 2013 |
July 11, 2008 |
September 26, 2014 |
|
- SEARCH Thailand
Bangkok, Thailand
|
| 3 |
NCT00708162 |
Completed
Has Results |
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir |
|
- Drug: Elvitegravir
- Drug: Raltegravir
- Drug: EVG placebo
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48
- Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 96
- Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 400 Copies/mL at Week 48
- (and 15 more...)
|
724 |
All |
18 Years and older (Adult, Senior) |
NCT00708162 |
GS-US-183-0145
2007-004225-26 |
|
July 2008 |
December 2010 |
April 2015 |
July 2, 2008 |
May 30, 2016 |
November 6, 2014 |
- Southwest Center for HIV/AIDS
Phoenix, Arizona, United States - Health for Life Clinic, PLLC
Little Rock, Arkansas, United States - Pacific Oaks Medical Group
Beverly Hills, California, United States - (and 177 more...)
|
| 4 |
NCT00698529 |
Active, not recruiting |
Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations |
|
- Behavioral: Face-to-face training
- Behavioral: Distance training
- Behavioral: Popular Opinion Leader (POL)
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adoption of the full Popular Opinion Leader intervention by a nongovernmental organization (NGO)
- Number of core elements of the Popular Opinion Leader intervention incorporated into NGO HIV prevention interventions
- Cost effectiveness of training method
|
99 |
All |
18 Years and older (Adult, Senior) |
NCT00698529 |
R01MH079730
DAHBR 9A-ASPQ |
|
November 2008 |
February 2013 |
December 2018 |
June 17, 2008 |
April 10, 2018 |
|
- Center for AIDS Intervention Research, Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 5 |
NCT00700284 |
Completed |
Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine) |
|
- Drug: placebo vaginal ring
- Drug: TMC120 (dapivirine) vaginal ring
|
Interventional |
Phase 1 |
- International Partnership for Microbicides, Inc.
- Tibotec Pharmaceutical Limited
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- safety and tolerability of a vaginal ring containing TMC120 (dapivirine)
- TMC120 (dapivirine) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma
|
12 |
Female |
18 Years to 50 Years (Adult) |
NCT00700284 |
IPM 001, TMC120-C130 |
|
October 2004 |
January 2005 |
January 2005 |
June 18, 2008 |
September 1, 2009 |
|
- Drug Research Unit, UZ Gent
Gent, Belgium
|
| 6 |
NCT00704249 |
Completed |
VENICE Study Nevirapine Full Dose/Dose Escalation |
|
|
Interventional |
Phase 4 |
- Clinical Trial Agency of HIV Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- The proportion of patients with a trough concentration of nevirapine in plasma within the therapeutic range (3000 to 8000 ng/mL) after 7 days of treatment.
- The proportion of patients with a plasma viral load of less than 50 copies/mL will be obtained. The change in CD4+ T-cell count will also be measured from baseline to weeks 4 and 12.
- The proportion of patients who experience adverse events (proportion of patients with exanthema and proportion of patients with liver toxicity)
- Proportion of patients with resolution of the neuropsychiatric adverse reaction to efavirenz that led to it being withdrawn
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT00704249 |
GESIDA-4905 |
VENICE |
July 2006 |
July 2008 |
February 2009 |
June 24, 2008 |
February 11, 2009 |
|
- Hospital General de Elche
Elche, Alicante, Spain - Hospital Germanas Trias i Pujol
Badalona, Barcelona, Spain - Hospital General de Granollers
Granollers, Barcelona, Spain - (and 12 more...)
|
| 7 |
NCT00705705 |
Completed |
Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks |
|
- Behavioral: Network leader training
- Behavioral: Standard HIV risk-reduction counseling
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Frequency of high-risk sexual practices
- Effectiveness and usefulness of HIV prevention intervention as a public health approach for reaching population segments that remain vulnerable to HIV and other STDs
|
852 |
All |
18 Years and older (Adult, Senior) |
NCT00705705 |
R01MH070316
DAHBR 9A-ASPQ |
|
July 2004 |
March 2009 |
September 2009 |
June 26, 2008 |
November 11, 2011 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 8 |
NCT00703248 |
Completed |
The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation Study |
|
- Procedure: Osteopathic Manipulative Treatments
|
Interventional |
Not Applicable |
- Nova Southeastern University
|
Other |
- Primary Purpose: Supportive Care
|
|
|
Male |
18 Years to 65 Years (Adult) |
NCT00703248 |
HPD-OST10030701 |
HOME |
October 2007 |
June 2008 |
June 2008 |
June 23, 2008 |
July 8, 2008 |
|
- Nova Southeastern University
Fort Lauderdale, Florida, United States
|
| 9 |
NCT00712530 |
Completed
Has Results |
Single DermaVir Immunization in HIV-1 Infected Patients on HAART |
|
- Biological: DermaVir
- Drug: HAART
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Grade 3 Adverse Event Related to DermaVir Treatment
- CD4+ T Cell Counts/mm3
- Number of Subjects With Detectable Anti-ds Antibody and ANA
- (and 2 more...)
|
9 |
All |
18 Years to 50 Years (Adult) |
NCT00712530 |
GIHU004 |
GIHU004 |
January 2005 |
June 2006 |
June 2006 |
July 10, 2008 |
March 26, 2013 |
March 26, 2013 |
- Saint Laszlo Hospital
Budapest, Hungary
|
| 10 |
NCT00711230 |
Unknown † |
Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients |
|
- Biological: DermaVir
- Biological: Placebo
|
Interventional |
Phase 2 |
- Genetic Immunity
- Universitätsklinikum Hamburg-Eppendorf
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent of participants with primary safety endpoint
- HIV-1 RNA
- CD4+ and CD8+ T-cell counts
- HIV-specific memory T cell responses
|
36 |
All |
18 Years to 50 Years (Adult) |
NCT00711230 |
DermaVir Phase II
2007-001955-20 |
GIEU006 |
April 2008 |
December 2011 |
January 2015 |
July 8, 2008 |
February 20, 2013 |
|
- ifi-Medizin GmbH at the Asklepios Klinik St. Georg
Hamburg, Germany - ICH Grindel
Hamburg, Germany - University Medical Center Hamburg-Eppendorf
Hamburg, Germany
|
| 11 |
NCT00703404 |
Completed |
Response to Standard HIV Treatment in Bamako, Mali |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
76 |
All |
18 Years and older (Adult, Senior) |
NCT00703404 |
999908160
08-I-N160 |
|
June 18, 2008 |
|
February 24, 2016 |
June 23, 2008 |
April 5, 2018 |
|
- University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology
Bamako, Mali
|
| 12 |
NCT00713531 |
Completed |
Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand |
|
|
Observational |
|
- South East Asia Research Collaboration with Hawaii
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- number of HIV-1 infections per 100 person-years
- Lost to follow-up on an annual basis (10% or better)
- Post-infection viral load and CD4 count
- (and 4 more...)
|
992 |
All |
18 Years to 50 Years (Adult) |
NCT00713531 |
SEARCH 008/RV233 |
|
July 2008 |
December 2009 |
June 2010 |
July 11, 2008 |
May 28, 2015 |
|
- The Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
| 13 |
NCT00703898 |
Completed |
Durability of Nevirapine-Based Antiretroviral Regimen |
|
|
Interventional |
Phase 4 |
- Bamrasnaradura Infectious Diseases Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients with undetectable plasma HIV-1 viral load
|
140 |
All |
15 Years and older (Child, Adult, Senior) |
NCT00703898 |
0327/3619 |
|
November 2004 |
December 2009 |
April 2010 |
June 24, 2008 |
July 8, 2008 |
|
- Department of Medicine, Bamrasnaradura Infectious Diseases Institute
Nonthaburi, Thailand
|
| 14 |
NCT00700115 |
Completed
Has Results |
Kaletra-isentress Treatment Evaluation |
|
- Drug: Kaletra + Isentress
- Drug: Pre-study antiretroviral regimen
|
Interventional |
Phase 4 |
- Emory University
- Abbott
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Viral Loads (HIV-1 RNA PCR)
- To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00700115 |
IRB00006876
KITE-6876 |
KITE |
June 2008 |
January 2011 |
January 2011 |
June 18, 2008 |
December 12, 2014 |
October 22, 2013 |
- Grady Infectious Diseases Program (Ponce Clinic)
Atlanta, Georgia, United States
|
| 15 |
NCT00702013 |
Completed |
Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Time Perspective: Cross-Sectional
|
- The activity and expression of P-glycoprotein at the time when the blood sample was taken.
|
310 |
All |
Child, Adult, Senior |
NCT00702013 |
P070102 |
Onto-Pgp |
March 2007 |
March 2009 |
August 2009 |
June 19, 2008 |
November 11, 2010 |
|
- Hopital Necker Enfants Malades
Paris, France
|
| 16 |
NCT00705679 |
Completed
Has Results |
Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women |
|
- Drug: Emtricitabine/tenofovir disoproxil fumarate
- Drug: Emtricitabine/tenofovir disoproxil fumarate placebo
- Drug: Tenofovir disoproxil fumarate
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Microbicide Trials Network
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
- Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
- Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
- (and 8 more...)
|
5029 |
Female |
18 Years to 45 Years (Adult) |
NCT00705679 |
MTN-003 (VOICE)
10622
MTN-003
5U01AI068633-05
VOICE |
|
August 2009 |
August 2012 |
August 2012 |
June 26, 2008 |
March 14, 2016 |
February 10, 2016 |
- Wits Reproductive Health and HIV Institute CRS (WRHI CRS)
Johannesburg, Gauteng, South Africa - Soweto MTN CRS
Johannesburg, Gauteng, South Africa - Overport CRS
Asherville, KwaZulu-Natal, South Africa - (and 12 more...)
|
| 17 |
NCT00709605 |
Completed |
Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection |
|
- Drug: VRC-HIVADV014-00-VP
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Safety (local and systemic reactogenicity, lab tests, AEs)
- Immunogenicity (cellular and humoral immune function assays)
|
31 |
All |
18 Years to 55 Years (Adult) |
NCT00709605 |
080171
08-I-0171 |
|
June 25, 2008 |
May 20, 2014 |
May 20, 2014 |
July 3, 2008 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 18 |
NCT00710593 |
Completed
Has Results |
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women |
|
- Biological: HPV vaccine for strains -6, -11, -16, and -18
|
Interventional |
Phase 2 |
- University of North Carolina, Chapel Hill
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- HPV-6 Antibody Level (Geometric Mean Titer of HPV-6)
- HPV-11 Antibody Level (Geometric Mean Titer of HPV-11)
- HPV-16 Antibody Level (Geometric Mean Titer of HPV-16)
- (and 22 more...)
|
99 |
Female |
16 Years to 23 Years (Child, Adult) |
NCT00710593 |
ATN 064 |
|
February 2008 |
February 2011 |
February 2011 |
July 4, 2008 |
July 2, 2017 |
May 22, 2017 |
- Childrens Hospital of Los Angeles
Los Angeles, California, United States - Childrens National Medical Center
Washington, D.C., District of Columbia, United States - Childrens Diagnostic & Treatment Center
Fort Lauderdale, Florida, United States - (and 11 more...)
|
| 19 |
NCT00736502 |
Completed
Has Results |
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice. |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of Patients Reporting Adverse Events
- Virologic Response (VR)
- Change in CD4+ Cell Count From Baseline to Week 48
|
280 |
All |
18 Years and older (Adult, Senior) |
NCT00736502 |
1100.1527 |
|
September 2008 |
July 2011 |
|
August 18, 2008 |
March 7, 2014 |
August 31, 2012 |
- Boehringer Ingelheim Investigational Site 1
Graz, Austria - Boehringer Ingelheim Investigational Site 2
Linz, Austria - Boehringer Ingelheim Investigational Site 3
Salzburg, Austria - (and 14 more...)
|
| 20 |
NCT00709111 |
Completed
Has Results |
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression |
|
|
Interventional |
Not Applicable |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in CD4+ T-cell Count
- Proportion of Participants Achieving a 50-cell Increase in CD4+ T-cell Count
- Within-subject CD4+ T-cell Count Slopes
- (and 17 more...)
|
34 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00709111 |
ACTG A5256
1U01AI068636 |
|
January 2009 |
October 2009 |
April 2010 |
July 3, 2008 |
February 3, 2016 |
February 24, 2012 |
- Alabama Therapeutics CRS (5801)
Birmingham, Alabama, United States - UCLA CARE Center CRS (601)
Los Angeles, California, United States - Stanford CRS (501)
Palo Alto, California, United States - (and 26 more...)
|
| 21 |
NCT00706550 |
Completed
Has Results |
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects |
|
- Biological: (PV) 23-valent pneumococcal polysaccharide vaccine
- Biological: Placebo
|
Interventional |
Not Applicable |
- VA Office of Research and Development
- Albert Einstein College of Medicine, Inc.
- Montefiore Medical Center
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Immunoglobulin G (IgG) Levels
- IgG Levels
- Immunoglobulin M (IgM) Levels
- (and 2 more...)
|
107 |
All |
18 Years and older (Adult, Senior) |
NCT00706550 |
INDA-002-08S |
|
October 2008 |
September 2011 |
September 2012 |
June 27, 2008 |
April 24, 2014 |
December 12, 2013 |
- Michael E DeBakey VA Medical Center
Houston, Texas, United States
|
| 22 |
NCT00705419 |
Completed |
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) |
|
- Drug: Vicriviroc maleate
- Drug: Placebo
- Drug: Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
|
Observational |
|
- Merck Sharp & Dohme Corp.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of malignancies, AIDS-defining events, other clinical events of importance, and death.
- Incidence of change in plasma viral tropism, time to change in plasma viral tropism, and change in HIV RNA and CD4+ counts, if available.
|
180 |
All |
18 Years and older (Adult, Senior) |
NCT00705419 |
P04999 |
COVER |
July 2007 |
September 2010 |
September 2010 |
June 26, 2008 |
February 5, 2015 |
|
|
| 23 |
NCT00703586 |
Completed |
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc |
|
|
Interventional |
Phase 1 |
- Rockefeller University
- Aaron Diamond AIDS Research Center
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT00703586 |
MMA-0612 |
|
September 2007 |
May 2011 |
May 2011 |
June 23, 2008 |
October 23, 2012 |
|
- Rockefeller University Hospital
New York, New York, United States
|
| 24 |
NCT00701896 |
Completed |
Smoking Cessation Using Motivational Therapy and Varenicline |
|
- Drug: Varenicline tartrate
- Drug: Nicotine Replacement Therapy
- Other: Biological Control
- Behavioral: Motivational Interview
|
Interventional |
Not Applicable |
- Philip Diaz
- National Heart, Lung, and Blood Institute (NHLBI)
- Ohio State University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To develop and evaluate a specialized smoking cessation intervention for the treatment of nicotine dependence in HIV-seropositive smokers.
- To examine the effects of smoking cessation on the course of lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema in a cohort of HIV-seropositive individuals.
- To explore the effects of smoking cessation on the biology of alveolar macrophages obtained from HIV-seropositive individuals
|
368 |
All |
18 Years and older (Adult, Senior) |
NCT00701896 |
2007H0173
R01HL090313 |
|
June 2008 |
April 20, 2013 |
June 20, 2013 |
June 19, 2008 |
February 13, 2017 |
|
- The Ohio State University
Columbus, Ohio, United States
|
| 25 |
NCT00705926 |
Completed |
Effectiveness of Antiretroviral Therapy During Acute HIV Infection |
|
- Drug: Highly Active Antiretroviral Therapy (HAART)
- Other: No treatment
|
Interventional |
Phase 1 |
- Massachusetts General Hospital
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in the level of HIV RNA at viral load set point if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment
- Difference in the level of CD4 cells if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment
- Difference in the level of HIV RNA and CD4 cell numbers between therapy initiated during acute HIV infection followed by terminal treatment interruption after at least 12 weeks of treatment and no therapy at 16 weeks after discontinuation of treatment
- Difference in the level of HIV at viral load set point and CD4 cell number at 72 weeks after study entry if therapy is initiated during acute HIV infection followed by terminal treatment interruption at 12 weeks versus at 32 weeks
|
25 |
All |
18 Years to 65 Years (Adult) |
NCT00705926 |
R01AI071915
RO1AIO71915 |
|
October 2008 |
February 7, 2013 |
July 16, 2017 |
June 27, 2008 |
August 31, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 26 |
NCT00696839 |
Completed |
Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects |
- HIV Infections
- Adverse Effects
|
- Behavioral: Cognitive-behavioral therapy
|
Interventional |
Not Applicable |
- Duquesne University
- Milton S. Hershey Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Side effect symptoms measured by visual analogue scales
- Health status by SF-36
- Adherence by visual analogue scale
- (and 2 more...)
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT00696839 |
#08-17 |
|
September 2008 |
June 2009 |
August 2009 |
June 13, 2008 |
March 2, 2010 |
|
- Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
|
| 27 |
NCT00710060 |
Completed |
Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations |
- HIV Infections
- Sexually Transmitted Diseases
|
- Behavioral: Community Popular Opinion Leader (C-POL)
- Behavioral: HIV/STD educational materials
|
Interventional |
Phase 3 |
- RTI International
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Frequency of unprotected sexual acts with nonspousal partners
- Overall observed incidence of sexually transmitted diseases (STDs) (e.g., chlamydia, gonorrhea, syphilis, trichomonas, HIV, or herpes simplex virus-2), as detected by biological specimens
- Increased exposure to HIV prevention messages, more STD treatment seeking, lower stigma regarding HIV and STDs, and lower substance abuse associated with sexual behavior in intervention group as compared to control group
|
18147 |
All |
18 Years to 49 Years (Adult) |
NCT00710060 |
U10MH061537
U10MH061499
U10MH061513
U10MH061536
U10MH061543
U10MH061544
DAHBR 9A-ASGT |
|
September 2002 |
August 2007 |
August 2007 |
July 3, 2008 |
November 4, 2013 |
|
- Fujian Institute of Health Education
Fuzhou, China - YRG Centre for AIDS Research and Education (YRGCARE)
Chennai, India - Universidad Peruana Cayetano Heredia
Lima, Peru - (and 2 more...)
|
| 28 |
NCT00703040 |
Completed |
Linkage to Care - Part I |
|
|
Observational |
|
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- Describe and evaluate community screening standards and practices.
- Describe and evaluate the relationships of screening venues with care-providing venues.
- Describe and evaluate referral and intake protocols.
- Describe and evaluate care adherence support (including support from both clinical and non-clinical sources).
|
35 |
All |
Child, Adult, Senior |
NCT00703040 |
ATN 066a |
|
March 2008 |
March 2010 |
March 2010 |
June 23, 2008 |
February 28, 2017 |
|
- Children's National Medical Center
Washington, District of Columbia, United States - Childrens Diagnostic&Treatment Center
Fort Lauderdale, Florida, United States - University of Miami School of Medicine
Miami, Florida, United States - (and 4 more...)
|
| 29 |
NCT00709007 |
Withdrawn |
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India |
- HIV Infections
- Heroin Dependence
|
- Behavioral: Directly Administered Antiretroviral Therapy (DAART)
- Behavioral: SAT
|
Interventional |
Phase 2
Phase 3 |
- Johns Hopkins University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIV RNA < 400 copies/ml
- Incidence of mortality and/or AIDS-defining illnesses
- Change in absolute CD4+ count from baseline
- Incidence of antiretroviral drug resistance
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00709007 |
R01DA018577-03S1 |
DAART+ |
July 2008 |
July 2010 |
July 2011 |
July 3, 2008 |
April 15, 2015 |
|
- YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR)
Chennai, Tamil Nadu, India
|
| 30 |
NCT00711009 |
Completed
Has Results |
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) |
- Human Immunodeficiency Virus Infection
|
- Drug: lopinavir/ritonavir (LPV/r)
- Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
- Drug: raltegravir (RAL)
|
Interventional |
Phase 3 |
- Abbott
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm
- Percentage of Participants With Moderate or Severe Treatment-emergent, Drug-related Adverse Events
- Primary Outcome: Percentage of Participants With Potentially Clinically Significant Laboratory Values
- (and 79 more...)
|
206 |
All |
18 Years and older (Adult, Senior) |
NCT00711009 |
M10-336
2008-000881-22 |
PROGRESS |
July 2008 |
November 2009 |
October 2010 |
July 8, 2008 |
February 14, 2012 |
February 2, 2011 |
- Site Reference ID/Investigator# 8431
Phoenix, Arizona, United States - Site Reference ID/Investigator# 8432
Beverly Hills, California, United States - Site Reference ID/Investigator# 8394
Atlantis, Florida, United States - (and 34 more...)
|
| 31 |
NCT00708110 |
Completed
Has Results |
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults |
- Infection, Human Immunodeficiency Virus
|
- Drug: GSK1349572
- Drug: Placebo
|
Interventional |
Phase 2 |
- ViiV Healthcare
- Shionogi
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11
- Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) and Over 24 Hours (AUC[0-24]) of GSK1349572 Following Dose Administration on Day 1
- Maximum Observed Plasma Concentration (Cmax) and Concentration at 24 Hours Post Dose (C24) of GSK1349572 Following Dose Administration on Day 1
- (and 22 more...)
|
35 |
All |
18 Years to 65 Years (Adult) |
NCT00708110 |
111521 |
|
June 2008 |
August 2008 |
August 2008 |
July 2, 2008 |
December 5, 2013 |
October 30, 2013 |
- GSK Investigational Site
Bakersfield, California, United States - GSK Investigational Site
Long Beach, California, United States - GSK Investigational Site
Newport Beach, California, United States - (and 15 more...)
|
| 32 |
NCT00710671 |
Completed |
Psychosocial Needs of YMSM |
|
|
Observational |
|
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- An understanding of the most salient risk factors/stressors and resistance factors/coping mechanisms that impact healthy identity development among YMSM living with HIV.
- An understanding of the association between ethnic identity, sexual identity, and identity as a young man living with HIV and the health behaviors of substance use, sexual activity, and adherence to healthcare among YMSM living with HIV.
- An understanding of the most salient risk factors/stressors and resistance factors/coping mechanisms that negatively impact the future life goals of YMSM living with HIV.
- (and 2 more...)
|
254 |
Male |
16 Years to 24 Years (Child, Adult) |
NCT00710671 |
ATN 070 |
|
March 2008 |
June 2009 |
June 2009 |
July 4, 2008 |
February 28, 2017 |
|
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of California at San Francisco
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 11 more...)
|
| 33 |
NCT00711386 |
Completed |
GSK706769 Repeat Dose Study |
- Infection, Human Immunodeficiency Virus
|
- Drug: GSK706769
- Other: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- GSK706769 safety parameters: the number of adverse events
- GSK706769 safety parameters: clinical safety labs from predose values.
- GSK706769 safety parameters: vital signs (blood pressure and heart rate) from predose values
- (and 7 more...)
|
40 |
All |
18 Years to 50 Years (Adult) |
NCT00711386 |
CRR111382 |
|
May 16, 2008 |
September 12, 2008 |
September 12, 2008 |
July 8, 2008 |
August 3, 2017 |
|
- GSK Investigational Site
Madison, Wisconsin, United States
|
| 34 |
NCT00709397 |
Terminated |
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy |
|
|
Observational |
|
- Brigham and Women's Hospital
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- first- and second-phase decay rates of plasma HIV-1 RNA
- 1. As exploratory analyses, to compare the observed first-phase decay rate of plasma HIV-1 RNA in treatment-experienced patients receiving raltegravir to treatment-naïve patients in other studies.
- 2. Quantify changes in the intracellular levels of HIV-1 proviral DNA and LTR circles during raltegravir therapy.
- 3. Correlate changes in the intracellular DNA compartments with first- and second-phase plasma HIV-1 RNA clearance rates.
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT00709397 |
2007-P-002410/1 |
|
June 2008 |
December 2009 |
December 2009 |
July 3, 2008 |
August 2, 2010 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States
|
| 35 |
NCT00703560 |
Completed |
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients |
|
|
Observational |
|
- University of Texas Southwestern Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison of interferon effectiveness (as measured by epsilon) in HIV/HCV to HCV alone and African American to Caucasians.
- SVR rate in HIV/HCV vs. HCV and African Americans vs. Caucasians
- Comparison of HCV quasi-species diversity
|
72 |
All |
18 Years and older (Adult, Senior) |
NCT00703560 |
102005-009
K23AI065630 |
VK |
September 2005 |
September 2011 |
January 2013 |
June 23, 2008 |
January 21, 2013 |
|
|
| 36 |
NCT00711906 |
Terminated |
Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy |
|
- Drug: Cotrimoxazole
- Drug: Sulfadoxine-pyrimethamine
|
Interventional |
Phase 3 |
- Institute of Tropical Medicine, Belgium
- Tropical Diseases Research Centre, Zambia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To test the hypothesis that co-trimoxazole prophylaxis is not inferior to SP intermittent preventive treatment in preventing placental malaria.
- To evaluate efficacy of CTX prophylaxis in preventing malaria peripheral parasitaemia.
- To evaluate efficacy of CTX prophylaxis in preventing perinatal mortality and in improving birth weight
- (and 8 more...)
|
352 |
Female |
Child, Adult, Senior |
NCT00711906 |
ITMP0108 |
|
February 2009 |
February 2010 |
September 2010 |
July 9, 2008 |
January 18, 2016 |
|
- Choma hospital
Choma, Zambia - Shampande Clinic
Shampande, Zambia
|
Create an RSS feed from your search for:
Download the search results for: